NCT02291913 - Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2014

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Breast Cancer

Interventions

DRUG

Everolimus

DRUG

Exemestane

Anti-estrogen therapy

DRUG

Tamoxifen

Anti-estrogen therapy

DRUG

Fulvestrant

Anti-estrogen therapy

DRUG

Anastrozole

Anti-estrogen therapy

DRUG

Letrozole

Anti-estrogen therapy

DRUG

Toremifine

Anti-estrogen therapy

Trial Locations (8)

32503

Woodlands Medical Specialists, Pensacola

33021

Memorial Cancer Center, Hollywood

33401

Florida Cancer Specialists-East, West Palm Beach

33916

Florida Cancer Specialists-South, Fort Myers

37203

Tennessee Oncology PLLC, Nashville

37404

Tennessee Oncology, Chattanooga

47802

Hope Cancer Center, Terre Haute

76104

Center for Cancer and Blood Disorders, Fort Worth